timolol brands

13 registered brands containing timolol in Zimbabwe.

Molecular formula: C13H24N4O3S

Timolol competes with adrenergic neurotransmitters for binding to beta(1)-adrenergic receptors in the heart and the beta(2)-receptors in the vascular and bronchial smooth muscle. This leads to diminished actions of catecholamines, which normally bind to adrenergic receptors and exert sympathetic effects leading to an increase in blood pressure and heart rate. Beta(1)-receptor blockade by timolol leads to a decrease in both heart rate and cardiac output during rest and exercise, and a decrease in both systolic and diastolic blood pressure. In addition to this, a reduction in reflex orthostatic hypotension may also occur. The blockade of beta(2) receptors by timolol in the blood vessels leads to a decrease in peripheral vascular resistance, reducing blood pressure. The exact mechanism by which timolol reduces ocular pressure is unknown at this time, however, it likely decreases the secretion of aqueous humor in the eye. According to one study, the reduction of aqueous humor secretion may occur through the decreased blood supply to the ciliary body resulting from interference with the active transport system or interference with prostaglandin biosynthesis. beta-Adrenergic blocker Following topical application to the eye, timolol maleate reduces both elevated and normal intraocular pressure in patients with or without open angle (chronic simple, noncongestive) glaucoma or ocular hypertension. Timolol reduces intraocular pressure with little or no effect on accommodation or pupillary size. In patients with elevated intraocular pressure, timolol reduces mean intraocular pressure by about 25-33%. The drug appears to be equally effective in light and dark colored eyes. ... The exact mechanism by which beta-blockers, including timolol, reduce intraocular pressure has not been clearly defined. Fluorophotometric studies suggest that reduced aqueous humor formation is the predominant effect. beta-Adrenergic blocking agents may block endogenous catecholamine stimulated increases in cyclic adenosine monophosphate concentrations within the ciliary processes and subsequent formation of aqueous humor. Timolol appears to cause little or no change in aqueous humor outflow facility. ... In some studies, timolol maleate applied topically to one eye reduced intraocular pressure in both eyes; the mechanism of this effect has not been elucidated. ... A slight decrease in the intraocular hypotensive effect may occur during the first 3 wk of timolol therapy, and tolerance may develop with prolonged use; however, the intraocular pressure lowering effect has been maintained for at least 3 yr with continuous use of the drug in some patients. /Timolol maleate/ Timolol maleate has pharmacologic actions similar to those of other beta-adrenergic blocking agents. The principal physiologic action of timolol is to competitively block beta-adrenergic receptors within the myocardium (beta1-receptors) and within bronchial and vascular smooth muscle (beta2-receptors). Unlike atenolol and metoprolol, timolol is not a beta1-selective adrenergic blocking agent; timolol is a nonselective beta-adrenergic blocking agent, inhibiting both beta1- and beta2-adrenergic receptors. Timolol also does not exhibit the intrinsic sympathomimetic activity seen with pindolol or the membrane stabilizing activity possessed by propranolol or pindolol. ... By inhibiting myocardial beta1-adrenergic receptors, timolol produces negative chronotropic and inotropic activity. The negative chronotropic action of timolol on the sinoatrial node results in a decrease in the rate of sinoatrial node discharge and an increase in recovery time, thereby decreasing resting and exercise stimulated heart rate and reflex orthostatic tachycardia by as much as 30%. High doses of the drug may produce sinus arrest, especially in patients with SA node disease (eg, sick sinus syndrome). Timolol also slows conduction in the atrioventricular node. Timolol usually produces a slight reduction in cardiac output, proba

Source: PubChem (NCBI) ยท compound 33624

Product Manufacturer Status Country
AZARGA
SUSPENSION/DROPS; OPHTHALMIC
Alcon-couvrier PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
BPROST-1
SOLUTION/DROPS; OPHTHALMIC
Indoco Remedies PRESCRIPTION PREPARATIONS 10TH SCHEDULE, (P.P.10) Zimbabwe
COMBIGAN
SOLUTION
Allergan PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
DORZIM
SOLUTION/DROPS; OPHTHALMIC
Indoco Remedies PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
DUOTRAV
SOLUTION/DROPS; OPHTHALMIC
Alcon Cusi PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
GANFORT
SOLUTION/DROPS; OPHTHALMIC
Allergan Pharmaceuticals PRESCRIPTION PREPARATIONS 10TH SCHEDULE, (P.P.10) Zimbabwe
IOPROST-T EYE DROPS
SOLUTION/DROPS; OPHTHALMIC
Fdc Limited PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
IOTIM
SOLUTION/DROPS; OPHTHALMIC
Fdc Limited PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
OCCUMOL
SOLUTION/DROPS; OPHTHALMIC
Amanta Healthcare PRESCRIPTION PREPARATIONS 10TH SCHEDULE, (P.P.10) Zimbabwe
OCUDOR-T
SOLUTION
Fdc Limited PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
TIMO-SOUTH
SOLUTION
Skymap Pharmaceuticals PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
TIMOLOL MALEATE
SOLUTION/DROPS; OPHTHALMIC
Caps PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
XALACOM
SOLUTION/DROPS; OPHTHALMIC
Pfizer PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe